CETP Inhibition with Anacetrapib - Impact on Atherogenic Lipoproteins
John Millar, Division of Translational Medicine and Human Genetics and Director of the Metabolic Tracer Resource in the Institute of Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania
The effect of anacetrapib on apolipoprotein (apo) B metabolism
John Millar's research interests focus on studying the mechanisms responsible for changes in lipid and lipoprotein metabolism in response to novel ... Tovább